Tissue Regenix Share Discussion Threads

[rayrac] 23/10/2015 08:35

A total commitment of over £3.6m!

But not one trade?! That's either criminal, or amazing. The radar must be switched off.

[rayrac] 23/10/2015 08:10

No-brainer, Ali. That's a lot of commitment!

[bamboo2] 23/10/2015 08:06

Non- Executive Director Share Purchase

York, 23 October 2015 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Company"), the regenerative medical devices company, today announces that on 21 October 2015 Alan Miller, Non-Executive Director of Tissue Regenix, acquired 400,000 ordinary shares of 0.5 pence at a price of 16.75p per share.

Following this transaction Alan Miller holds 21,886,988 ordinary shares which represents a total of 2.88% of the Company's issued share capital.

[ali47fish] 23/10/2015 08:03

non exec dir buying- should we follow him?

[rayrac] 23/10/2015 08:03

Miller spends £67,000 on shares!

He knows ya know....

[rayrac] 17/10/2015 12:58

I've just become a non paying member of advfn. I'm wondering what effect it will have on my ability to access the site?

[grahamburn] 17/10/2015 10:00

No problem, I know the feeling/issues about keeping abreast of multiple companies' activities and financing! Happy to help you.

[muckshifter] 16/10/2015 19:26

Yes you are right in this case grahamburn. Hadn't read the company's results since last year's finals a few months ago, and for some reason was convinced that they were down to about £5m cash, probably because I read many results RNSs and mixed up two companys' results.

The complete lack of discussion of financial situation, in what was an excellent presentation, threw me a bit, and I should have looked back at the last results RNS. Apologies to anyone who was troubled by my post.
Regards.

[grahamburn] 16/10/2015 17:27

muckshifter. With respect, you don't seem to have done much research on this company's past fundraisings and its current major shareholders. All of them have supported the company on a long term basis throughout major fundraisings.

Almost 60% of the shares are held by just three entities, with directors also holding significant amounts.

In short it's probable that, as and when required, additional funds are sought, there would be similar support; unless, of course, the product portfolio loses momentum.

Unlikely, IMHO, based upon the presentation.

[rayrac] 16/10/2015 13:31

Yes bam, thanks much for your efforts. Greatly appreciated!

[muckshifter] 16/10/2015 12:47

Thanks for the link to the presentation bamboo2. Very encouraging presentation, with the only disappointment, imho, being that no one mentioned money in the Q&A at the end. I'm sure they are still going to need a large cash infusion, or a few small ones, before reaching cash breakeven, but I suppose it was to much to expect them to give any indications on how that would be achieved.

My hope is that they do a biggie similar to the recent ReNeuron one, where an institution with long term vision makes a serious medium / long term commitment without demanding a huge placing discount.
Perhaps with a rights issue at the same time.
Regards.

[rayrac] 16/10/2015 12:18

Better in than out!

[grahamburn] 15/10/2015 14:51

Igbert. End of conversation, I think.

Like you suggested I was originally guilty of not answering your question (which I subsequently did), you clearly don't wish to consider any alternative view to your own!

We both believe we have "evidence", but it's just not worth continuing a non-conversation as it won't enlighten anyone else.

[igbertsponk] 15/10/2015 14:22

Graham - I've paid Edison to produce a few over the years. They know the score ;-)

[grahamburn] 15/10/2015 14:09

Yes.

Matchtec earlier this year, to name one from memory, which was nowhere near as bullish as previous reports. I could, if I searched back through my folder of Edison reports, find others, but cannot be bothered to pursue a discussion based on sweeping unsubstantiated statements.

However, in the spirit of friendship, your original statement may well be correct provided you qualified it with a phrase such as "All Edison initiation of coverage reports are/tend to be bullish."

[igbertsponk] 15/10/2015 09:34

graham - answer the question - have you ever seen an Edison note that isn't bullish?

[grahamburn] 15/10/2015 09:16

Igbert.

That's a sweeping statement about Edison. Though the firm is indeed retained by companies to produce notes on them, if you follow those reports through on a regular basis, then Edison's view does change over time. OK, it's not always "if the facts change, then we change our view", there is an element of realism and objectivity in most of their reports.

As with any analysts' reports, the reader has to be objective as well!

[igbertsponk] 15/10/2015 08:57

Has anyone ever seen an Edison note (that TRX will have paid Edison to produce) that wasn't bullish? Always to be taken with a pinch of salt but nice to see anyway.

[swiss paul] 14/10/2015 21:51

and the in house broker is?

[bamboo2] 14/10/2015 18:30

float, you could try a search for the number of Knee Arthroscopy procedures. Many of these will involve meniscus and/or ACL treatments.

[bamboo2] 14/10/2015 18:22

Thanks Ray.

London, UK, 14 October 2015

Edison initiates coverage of Tissue Regenix

Tissue Regenix's (TRX) investment story is built on dCELL, a versatile regenerative medical technology, and its potential across the subsectors: wound care, orthopaedics and cardiac implants. We forecast that the US Wound Care subsidiary will be a driver of rapid group sales growth from the FY15 starting point of GBP0.1m, rising to GBP74m in FY21 boosted by product launches from all three divisions.

Our sum-of-the-parts DCF valuation is GBP325m, or 43p/share, using a 12.5% WACC. We value the wound care franchise at GBP175m, orthopaedics at GBP95m and the cardiac division at GBP35m. The current market capitalisation, which is subject to an estimated funding requirement of GBP15m needed to develop OrthoPure XT and XM in the US, does not reflect the full pipeline potential, which could ultimately be attractive to larger medtech companies.

Click here to view the full report

[rayrac] 14/10/2015 17:20

That's a very late note to the market from Edison! Hence the late tick up in sp? All appears very bullish!

[floatupstream] 13/10/2015 08:56

In the interims the potential market sized as 1.5million people suffering meniscal injuries in the USA and EU per year. I'm interested to get an idea what percentage of those people actually have kneecap surgery though?

[bamboo2] 13/10/2015 08:28

Re, the Webcast from yesterdays CMD. You can watch this in sections by clicking on the slides. This advances the commentary to the appropriate place.

Greg Bila and Patti Gary's contributions are outstanding, as are the clinical results.

John D. Thomas, MD, PCWC is an advocate of TRX. He is a senior healthcare professional with direct experience of ALL the woundcare products currently on the market. They have all failed one way or another EXCEPT Dermapure.

Setting up a Patients Registry and using Healthcare Proffessionals as Advocates are great ideas that could become a bedrock of the sales process.

Peter Hamer, I found myself dropping off, but it was getting late. Worth watching the vid he presents from David Houlihan Burne.

The meniscus product is looking very good.